DMHC analysts discuss presentations from the Advanced Therapies conference

Supporting links
Cell and Gene Therapy Podcast
https://www.biomedtracker.com/reportdetail.cfm?reportid=1683

Editing The Future Report
https://www.biomedtracker.com/reportdetail.cfm?reportid=1608

Peripheral T-Cell Lymphoma (PTCL) Market Spotlight
https://www.biomedtracker.com/reportdetail.cfm?reportid=1050

Gene, Cell, & RNA Therapy Landscape Q4 2022 Report
https://www.biomedtracker.com/reportdetail.cfm?reportid=1721

Other platforms
Apple Podcasts -   https://podcasts.apple.com/us/podcast/pharma-intelligence-podcasts/id923189836​

Google Podcasts - https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5zb3VuZGNsb3VkLmNvbS91c2Vycy9zb3VuZGNsb3VkOnVzZXJzOjEwNjU1NDkyOC9zb3VuZHMucnNz​

TuneIn - https://tunein.com/podcasts/Business--Economics-Podcasts/Pharma-Intelligence-Podcasts-p1140128/​

Spotify Podcasts - https://open.spotify.com/show/3DTc3eIh4xI6pVOd6DdO67​

DMHC podcast - Advanced Therapies

Commercialization is a tough road to navigate even for the most established bio/pharmaceutical therapies. But as cell and gene therapies (CGTs) continue to form roots and make a splash worldwide—but specifically in the US—commercialization forms its own version of standardization and best practices.  

In this exclusive interview with Pharmaceutical Executive, Lung-I Cheng, vice president of CGT, Cencora (formerly AmerisourceBergen), discusses: 
1) defining CGT commercialization strategies and foundational knowledge—and the best music metaphor
2) what he wishes companies knew about commercialization strategies
3) common knowledge gaps of CGTs
4) how CGT developers can overcome key challenges, including those related to patient access, regulatory requirements, and market access
5) how planning for allogeneic cell therapies differs from autologous cell therapies and gene therapies
6) how companies can demonstrate CGT value as more products enter the development pipeline (and competition intensifies)
7) when to start planning a CGT commercialization strategy
8) predictions for the CGT market in five years

Avoiding Commercialization Pitfalls for CGTs

In the latest episode of the In Vivo podcast, Edwin Stone, CEO of UK-based Cellular Origins, talks about how robotics can increase access to safe cellular therapies. The type of biology-agnostic robotics his company develops can help companies scale up cell manufacturing while lowering the cost of production.

Automating Cell Therapy Manufacturing: Cellular Origins' CEO Talks Robotics

Tevard Biosciences CEO Daniel Fischer discusses how engineered suppressor tRNAs enable read-through of premature stop codons to restore full-length protein production in genetic diseases. Fischer, whose daughter has Dravet syndrome, covers the company's lead programs in dilated cardiomyopathy and DMD, advantages over traditional gene therapy approaches, and the path to human proof-of-concept.

Tevard CEO Sees Hope for HIs Daughter In His Company's tRNA Platform

Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.

New tracks tagged #cellandgenetherapy